SCHEDULE: 3i LP Updates Pelthos Therapeutics Stake to 9.99%

3i, LP, along with 3i Management LLC and Maier Joshua Tarlow, updated their beneficial ownership in Pelthos Therapeutics Inc. to 9.99% of common stock.

Summary

• Reporting persons (3i, LP, 3i Management LLC, and Maier Joshua Tarlow) collectively beneficially own 318,886 shares of Pelthos Therapeutics Inc. common stock.
• This represents 9.99% of the company's outstanding common stock, based on 3,086,681 shares outstanding as of November 24, 2025.
• The ownership includes 213,507 directly held common shares and 105,379 shares convertible from Series A Convertible Preferred Stock and a $1,000,000 senior secured convertible note.
• Conversion of the preferred stock and note is subject to a 9.99% beneficial ownership blocker, prohibiting ownership from exceeding this threshold.
• This filing is an Amendment No. 1 to a previously filed Schedule 13G.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive update, confirming a significant institutional stake and the continued presence of convertible instruments, which are typical for growth-stage companies like Pelthos Therapeutics.

Positives

• A significant institutional investor group maintains a substantial stake in Pelthos Therapeutics, indicating continued interest.
• The beneficial ownership blocker limits potential dilution from conversions by capping the percentage at 9.99%.

Negatives

• The filing does not indicate an increase in the percentage of ownership beyond the 9.99% threshold, suggesting no immediate aggressive accumulation.
• The existence of a convertible note and preferred stock, even with a blocker, represents potential future dilution up to the 9.99% cap.

Risks

• Potential future dilution from the conversion of Series A Convertible Preferred Stock and the senior secured convertible note, up to the 9.99% beneficial ownership blocker.
• The reporting persons explicitly state that the securities were not acquired for the purpose of changing or influencing control of the issuer, which might limit activist potential.

Future Outlook

The filing primarily updates beneficial ownership information and does not provide explicit forward-looking statements or guidance from Pelthos Therapeutics Inc. The reporting persons' ownership structure, including convertible instruments, suggests a continued long-term interest in the company, subject to the 9.99% beneficial ownership blocker.

Management Comments

• The filing of this Amendment No. 1 should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of Common Stock reported herein.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that institutional ownership updates like this Schedule 13G/A are common in the biotechnology and pharmaceutical sectors, where early-stage companies often rely on convertible debt and preferred equity financing. A 9.99% stake is a significant, but not controlling, position, often reflecting a strategic investment without triggering more stringent reporting requirements or activist intentions.

Comparison to Industry Standards

• StockSavvy.ai observes that a 9.99% beneficial ownership stake is a common threshold for institutional investors to maintain significant influence without crossing the 10% mark, which can trigger additional regulatory burdens and reporting requirements under Section 16 of the Exchange Act.
• This strategy is frequently employed by funds like 3i, LP, which specialize in strategic investments in growth-oriented companies, similar to how funds like Orbimed or RA Capital Management might structure their early-stage biotech investments to balance influence with regulatory compliance.

Stakeholder Impact

• Shareholders: The continued significant stake by 3i, LP, provides a level of institutional backing. Potential future dilution from conversions is capped by the blocker.
• Creditors: The senior secured convertible note held by 3i, LP, indicates a creditor relationship that can convert to equity.

Next Steps

• Pelthos Therapeutics Inc. will continue its operations.
• The reporting persons may convert their preferred stock and convertible note into common stock, subject to the 9.99% beneficial ownership blocker.

Key Dates

Recommendation

This filing is a routine update of beneficial ownership by an existing institutional investor. It confirms a significant, but not controlling, stake and the presence of convertible instruments. There are no new material developments that would fundamentally alter the investment thesis for Pelthos Therapeutics Inc. at this time, warranting a 'hold' recommendation for existing investors.

Keywords

Pelthos Therapeutics, PTIX, 3i LP, Schedule 13G, Beneficial Ownership, Common Stock, Convertible Preferred Stock, Convertible Note, SEC Filing, Institutional Investor, Biotechnology, Pharmaceuticals